Navigation Links
Rapamycin rescues learning, memory in Alzheimer's mouse model
Date:2/24/2010

SAN ANTONIO (Feb. 24, 2010) Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.

Rapamycin rescued learning and memory deficits in a mouse model of Alzheimer's, a team from The University of Texas Health Science Center at San Antonio reported Tuesday (Feb. 23).

The study, in the Journal of Biological Chemistry, offers the first evidence that the drug is able to reverse Alzheimer's-like deficits in an animal model, said the senior author, Salvatore Oddo, Ph.D., assistant professor in the Department of Physiology of the UT Health Science Center San Antonio.

Tissue evidence

Rapamycin also reduced lesions in the brains of the mice, the team found. The lesions are similar to those seen in the brains of people who died with Alzheimer's.

"Our findings may have a profound clinical implication," said Dr. Oddo, who is a member of the university's Barshop Institute for Longevity and Aging Studies. "Because rapamycin is a U.S. Food and Drug Administration-approved drug, a clinical trial using it as an anti-Alzheimer's disease therapy could be started fairly quickly."

Last year three institutions, including the Barshop Institute, announced that rapamycin extended the life span of aged research mice at each of the sites. It was the first pharmacologic intervention shown to extend life in an animal model of aging.

Study method

For 10 weeks the mice that model Alzheimer's disease were fed chow containing rapamycin. At the start of treatment the mice were 6 months old, roughly the age of young adults, but already exhibited indications of learning and memory deficits and brain lesions.

At the end of the 10 weeks, the mice were tested in a contraption called the Morris water maze, sort of a miniature swimming pool used to assess learning and memory in rodents. At the end of the behavioral tests, the brains of the mice were analyzed to determine the effects of rapamycin on the lesions that indicate Alzheimer's.

Promise remains to be determined

Rapamycin, a bacterial product first isolated in soil from the island Rapa Nui in the South Pacific, also is being tested in cancer research studies. Rapa Nui is commonly known as Easter Island and is distinguished by ancient monoliths with faces.

"While it remains to be determined whether our results obtained in mice could be translated in people, we are very excited as these findings may lead to a new therapeutic intervention to treat Alzheimer's," Dr. Oddo said.


'/>"/>

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio
Source:Eurekalert  

Related medicine news :

1. New form of stem cell communication rescues diseased neurons
2. Drug rescues memory lost to Alzheimers disease
3. Petfinder.com Foundation Rescues 500 Shelters and Rescue Groups Nationwide with $1 Million Worth of Generators
4. Chicago Mayor Honors Astellas Excellence in Learning, Development
5. KMSI Announces KMx Update That Provides eLearning, Knowledge Management and Collaboration Tools for Apple iPhone and Other Mobile Devices
6. Engineer: Computer learning, electrical stimulation offer hope for paralyzed
7. Brain Switchboard Separates Learning, Remembering
8. Brain scientist shedding light on learning, memory
9. Bioethics memory aid can help assess patient decision-making capacity in medical emergencies
10. Memory Loss Supplement Manufacturer Partners With Nationally-Syndicated Radio Host John Tesh
11. To Boost Your Memory, Take a Break
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rapamycin rescues learning, memory in Alzheimer's mouse model
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... MINNEAPOLIS , Feb. 10, 2016 Urologix, ... for the treatment of Benign Prostatic Hyperplasia (BPH), announces ... Ash Keswani , a medical device industry veteran ... of the Limited Liability Company.  ... and service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... -- Oxis International Inc. (OTC/QB: OXIS) announced today that the ... "clinical trial triumph" after one of the first patients ... Daniel Vallera , a research scientist ... --> Daniel Vallera , a research scientist ... --> An article on the University of ...
Breaking Medicine Technology: